Novartis Produces First Swine Flu Vaccine

Novartis AG has completed production of the first batch of swine flu vaccine weeks ahead of time as its cell-based method proved faster than an egg-based approach.

The 10-liter batch of wild-type H1N1 vaccine will be used for pre-clinical tests and is being considered for use in human trials, Basel, Switzerland-based Novartis said in an e-mailed statement today, Bloomberg reported.

Based on the results with the wild- type vaccine, Novartis expects to gain approval for manufacture with reassortant seed in the fall.

Novartis has more than 30 requests from governments to supply them with H1N1 vaccine ingredients.

The virus known as swine flu, causing mostly mild disease outbreaks on four continents, prompted the World Health Organization to declare Thursday the first influenza pandemic since 1968.

We need your support so Novinite.com can keep delivering news and information about Bulgaria! Thank you!